Sector News

BMS to pay up to $1.56bn for Agenus’ bispecific antibody programme

May 23, 2021
Life sciences

Bristol Myers Squibb (BMS) has agreed an exclusive license deal for Agenus’ bispecific antibody programme, gaining access to the company’s preclinical anti-TIGIT asset.

Agenus’ AGEN1777 is a preclinical antibody candidate designed to target major inhibitory receptors expressed on T and NK cells to bolster anti-tumour activity by blocking TIGIT and a second undisclosed target.

In preclinical studies, using this approach has demonstrated potential in tumour models where anti-PD-1 or anti-TIGIT monospecific antibodies alone are not effective.

BMS will pay Agenus $200m upfront and up to $1.36bn in development, regulatory and commercial milestones as well as tiered double-digit royalties on net product sales as part of the agreement.

In return, BMS will become solely responsible for the development and subsequent commercialisation of AGEN1777 and any related products globally.

Under the terms of the agreement, Agenus will retain options to conduct clinical studies under the development plan and undertake combination studies with some of its other pipeline assets.

Agenus can also choose to co-promote AGEN1777 in the US, depending upon commercialisation of the asset.

“AGEN1777’s differentiated mechanism of action provides the potential for potent anti-tumour activity; catalysing our clinical TIGIT strategy aimed at serving more patients with unmet needs in cancer,” said Debbie Law, senior vice president, head of tumour microenvironment thematic research centre, BMS.

“We look forward to working with Agenus to develop this important therapy as we continue to combat I-O resistance,” she added.

Agenus is planning to file an investigational new drug application (IND) for AGEN1777 with the US Food and Drug Administration (FDA) in the second quarter of the year.

Meanwhile, BMS will advance the research and development of the bispecific antibody in immuno-oncology for ‘high priority’ tumour indications such as non-small cell lung cancer (NSCLC).

by Lucy Parsons

Source: pharmatimes.com

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach